FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994482184> ?p ?o ?g. }

• W1994482184 endingPage "55" @default.
• W1994482184 startingPage "45" @default.
• W1994482184 abstract "Objective: EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia. Here, we present data from Pakistan. Methods: This was a 26-week observational, multicenter, prospective, open-label study. At week 26, change from baseline in mean sitting systolic (msSBP) and diastolic blood pressure (msDBP) and the proportion of patients achieving BP goal (SBP/DBP <140/90 mmHg; <130/80 mmHg in patients with diabetes) and response rates (SBP <140 mmHg [130 mmHg for patients with diabetes] or reduction of ≥20 mmHg; DBP <90 mmHg [80 mmHg for patients with diabetes] or reduction of ≥10 mmHg), were evaluated. Incidence of adverse events (AEs) and serious AEs (SAEs) was recorded as safety variables. Subjective assessment of effectiveness, compliance and tolerability was done by the physician. Results: A total of 500 patients with hypertension (mean age of 48 years) were prescribed Aml/Val ( n = 471, 94%) or Aml/Val/HCTZ ( n = 29, 6%); 439 (87.8%) patients completed the study. At week 26, the mean BP decreased from 153.4/91.1 mmHg at baseline to 128.9/78.4 mmHg in the Aml/Val cohort (−24.5/−12.7 mmHg; p < 0.0001) and from 171.6/99.3 mmHg at baseline to 127.7/77.4 mmHg (−43.9/−21.9 mmHg; p < 0.0001) in the Aml/Val/HCTZ cohort. BP goals were achieved by 57% and 55.2% of patients in the Aml/Val and Aml/Val/HCTZ cohorts, respectively. A total of 40 (8%) patients reported at least one AE during the study period. Most common AEs included nausea (1.6%), headache (1.2%), vomiting (1.2%), and edema (1.2%). Most patients in Aml/Val cohort and all patients in Aml/Val/HCTZ cohort rated the effectiveness, compliance and tolerability as ‘good’ or ‘very good’. Conclusions: Aml/Val with or without HCTZ in a SPC was effective and well-tolerated for BP reduction in this cohort of patients with hypertension from Pakistan." @default.
• W1994482184 created "2016-06-24" @default.
• W1994482184 creator A5001115490 @default.
• W1994482184 creator A5006747701 @default.
• W1994482184 creator A5035594240 @default.
• W1994482184 creator A5047374840 @default.
• W1994482184 creator A5054626999 @default.
• W1994482184 creator A5055117301 @default.
• W1994482184 creator A5056349205 @default.
• W1994482184 creator A5057750899 @default.
• W1994482184 creator A5068914134 @default.
• W1994482184 creator A5081233284 @default.
• W1994482184 date "2014-02-20" @default.
• W1994482184 modified "2023-10-10" @default.
• W1994482184 title "Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan" @default.
• W1994482184 cites W1585441327 @default.
• W1994482184 cites W1669590341 @default.
• W1994482184 cites W1975270946 @default.
• W1994482184 cites W1979481917 @default.
• W1994482184 cites W1981239495 @default.
• W1994482184 cites W1991495732 @default.
• W1994482184 cites W2003301562 @default.
• W1994482184 cites W2003548132 @default.
• W1994482184 cites W2009820178 @default.
• W1994482184 cites W2043244508 @default.
• W1994482184 cites W2044170646 @default.
• W1994482184 cites W2044285488 @default.
• W1994482184 cites W2067064224 @default.
• W1994482184 cites W2097624585 @default.
• W1994482184 cites W2110052313 @default.
• W1994482184 cites W2116717490 @default.
• W1994482184 cites W2121490027 @default.
• W1994482184 cites W2131494018 @default.
• W1994482184 cites W2133107047 @default.
• W1994482184 cites W2133416234 @default.
• W1994482184 cites W2133617016 @default.
• W1994482184 cites W2148025183 @default.
• W1994482184 cites W2154052522 @default.
• W1994482184 cites W2156121263 @default.
• W1994482184 cites W2170857690 @default.
• W1994482184 doi "https://doi.org/10.1177/1753944714525496" @default.
• W1994482184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24562476" @default.
• W1994482184 hasPublicationYear "2014" @default.
• W1994482184 type Work @default.
• W1994482184 sameAs 1994482184 @default.
• W1994482184 citedByCount "11" @default.
• W1994482184 countsByYear W19944821842016 @default.
• W1994482184 countsByYear W19944821842018 @default.
• W1994482184 countsByYear W19944821842020 @default.
• W1994482184 countsByYear W19944821842021 @default.
• W1994482184 countsByYear W19944821842022 @default.
• W1994482184 countsByYear W19944821842023 @default.
• W1994482184 crossrefType "journal-article" @default.
• W1994482184 hasAuthorship W1994482184A5001115490 @default.
• W1994482184 hasAuthorship W1994482184A5006747701 @default.
• W1994482184 hasAuthorship W1994482184A5035594240 @default.
• W1994482184 hasAuthorship W1994482184A5047374840 @default.
• W1994482184 hasAuthorship W1994482184A5054626999 @default.
• W1994482184 hasAuthorship W1994482184A5055117301 @default.
• W1994482184 hasAuthorship W1994482184A5056349205 @default.
• W1994482184 hasAuthorship W1994482184A5057750899 @default.
• W1994482184 hasAuthorship W1994482184A5068914134 @default.
• W1994482184 hasAuthorship W1994482184A5081233284 @default.
• W1994482184 hasBestOaLocation W19944821841 @default.
• W1994482184 hasConcept C126322002 @default.
• W1994482184 hasConcept C164705383 @default.
• W1994482184 hasConcept C197934379 @default.
• W1994482184 hasConcept C2777387769 @default.
• W1994482184 hasConcept C2778375690 @default.
• W1994482184 hasConcept C2779646130 @default.
• W1994482184 hasConcept C2780361556 @default.
• W1994482184 hasConcept C71924100 @default.
• W1994482184 hasConcept C84393581 @default.
• W1994482184 hasConceptScore W1994482184C126322002 @default.
• W1994482184 hasConceptScore W1994482184C164705383 @default.
• W1994482184 hasConceptScore W1994482184C197934379 @default.
• W1994482184 hasConceptScore W1994482184C2777387769 @default.
• W1994482184 hasConceptScore W1994482184C2778375690 @default.
• W1994482184 hasConceptScore W1994482184C2779646130 @default.
• W1994482184 hasConceptScore W1994482184C2780361556 @default.
• W1994482184 hasConceptScore W1994482184C71924100 @default.
• W1994482184 hasConceptScore W1994482184C84393581 @default.
• W1994482184 hasIssue "2" @default.
• W1994482184 hasLocation W19944821841 @default.
• W1994482184 hasLocation W19944821842 @default.
• W1994482184 hasOpenAccess W1994482184 @default.
• W1994482184 hasPrimaryLocation W19944821841 @default.
• W1994482184 hasRelatedWork W1994482184 @default.
• W1994482184 hasRelatedWork W1995634122 @default.
• W1994482184 hasRelatedWork W2007089169 @default.
• W1994482184 hasRelatedWork W2014136873 @default.
• W1994482184 hasRelatedWork W2048608125 @default.
• W1994482184 hasRelatedWork W2074016613 @default.
• W1994482184 hasRelatedWork W2138802908 @default.
• W1994482184 hasRelatedWork W2144809272 @default.
• W1994482184 hasRelatedWork W2155340671 @default.
• W1994482184 hasRelatedWork W4288070457 @default.
• W1994482184 hasVolume "8" @default.

• next